Free Webinar: Using Big Data Like Biomarkers to Advance Clinical Development & Commercialization

You have been chosen to receive this valuable information.

What if you could use predictive models like biomarkers to pre-emptively screen and more effectively target patients who are more likely to respond to your drug in trials and in practice?

What if you could rapidly answer questions on comparative treatment outcomes and predict those most likely to have an adverse event?

The convergence of AI and big data enable the ability to measure, predict and personalize care in a way previously not possible.

Join Dr. Richard Gliklich, CEO of OM1, as he explores different ways you can use big data and AI to advance drug development and commercialization, including:

Identifying under-diagnosed patients
Identifying likely responders in trials and in practice
Predicting which patients have the most potential for adverse events
Comparing and predicting treatment outcomes across different populations

Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of Pharmaceutical Executive, a UBM publication. You are on the mailing list as %%emailaddress%%.